Compare · AMGN vs MGX
AMGN vs MGX
Side-by-side comparison of Amgen Inc. (AMGN) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $178.70B, about 3319.4x MGX ($53.8M).
- Over the past year, AMGN is up 20.0% and MGX is down 0.7% - AMGN leads by 20.7 points.
- AMGN has been more active in the news (21 items in the past 4 weeks vs 3 for MGX).
- AMGN has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- Amgen Inc.
- Metagenomi Therapeutics Inc.
- Price
- $331.06+0.46%
- $1.44+2.86%
- Market cap
- $178.70B
- $53.8M
- 1M return
- -2.63%
- +5.49%
- 1Y return
- +20.03%
- -0.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2024
- News (4w)
- 21
- 3
- Recent ratings
- 25
- 8
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- EVP, Operations Santos Esteban covered exercise/tax liability with 1,338 shares, decreasing direct ownership by 2% to 81,066 units (SEC Form 4)
- EVP & Chief Technology Officer Reese David M covered exercise/tax liability with 1,433 shares, decreasing direct ownership by 3% to 40,354 units (SEC Form 4)
- SVP, Human Resources Miller Derek covered exercise/tax liability with 365 shares, decreasing direct ownership by 3% to 11,808 units (SEC Form 4)
- SVP, Business Development Khosla Rachna covered exercise/tax liability with 225 shares, decreasing direct ownership by 3% to 8,066 units (SEC Form 4)
- SVP & CCO Grygiel Nancy A. covered exercise/tax liability with 242 shares and sold $400,451 worth of shares (1,237 units at $323.73), decreasing direct ownership by 17% to 7,009 units (SEC Form 4)
- EVP & CFO Griffith Peter H. covered exercise/tax liability with 1,433 shares, decreasing direct ownership by 3% to 47,568 units (SEC Form 4)
- EVP & Gen. Counsel & Sec. Graham Jonathan P covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 3% to 38,010 units (SEC Form 4)
- EVP, Global Commercial Ops Gordon Murdo covered exercise/tax liability with 1,593 shares, decreasing direct ownership by 3% to 48,699 units (SEC Form 4)
- VP, Finance & CAO Busch Matthew C. covered exercise/tax liability with 68 shares, decreasing direct ownership by 2% to 3,980 units (SEC Form 4)
- Chairman, CEO and President Bradway Robert A covered exercise/tax liability with 5,057 shares, decreasing direct ownership by 1% to 496,805 units (SEC Form 4)
Latest MGX
- SEC Form DEFA14A filed by Metagenomi Therapeutics Inc.
- SEC Form DEF 14A filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
- SEC Form 4 filed by Irish Jian
- SEC Form 4 filed by Wein Matthew
- SEC Form 4 filed by Wapnick Pamela
- Chief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)
- Officer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)
- Chief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)
- SEC Form S-8 filed by Metagenomi Therapeutics Inc.